Hexylcaine

CHEMBL1197 Phase 4 Aprovado Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
261.4 g/mol
LogP
3.6
Phase
4

A local anesthetic that blocks sodium channels in nerve cell membranes to prevent pain signal transmission, used topically for anesthesia of mucous membranes in procedures such as endoscopy. It was used historically for topical anesthesia but has largely been replaced by agents with better-established safety profiles. Its mechanism of action is similar to other ester-type local anesthetics.

Peso Molecular

261,3600 g/mol

LogP

3,60

TPSA

38,30 Ų

Regra dos 5 de Lipinski

Aprovado

Mecanismo de Ação

Blocks voltage-gated sodium channels in nerve cell membranes, preventing the generation and conduction of nerve impulses. This produces reversible loss of sensation in the area of application.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

Blocks voltage-gated sodium channels in nerve cell membranes, preventing the generation and conduction of nerve impulses. This produces reversible loss of sensation in the area of application.

Estrutura 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC(CNC1CCCCC1)OC(=O)c1ccccc1

InChI

InChI=1S/C16H23NO2/c1-13(12-17-15-10-6-3-7-11-15)19-16(18)14-8-4-2-5-9-14/h2,4-5,8-9,13,15,17H,3,6-7,10-12H2,1H3

Molecular Formula

C16H23NO2

HBD / HBA

1 / 3

Ligações Rotacionáveis

6

Átomos Pesados

19

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Perguntas frequentes

A local anesthetic that blocks sodium channels in nerve cell membranes to prevent pain signal transmission, used topically for anesthesia of mucous membranes in procedures such as endoscopy. It was used historically for topical anesthesia but has largely been replaced by agents with better-established safety profiles. Its mechanism of action is similar to other ester-type local anesthetics.

Blocks voltage-gated sodium channels in nerve cell membranes, preventing the generation and conduction of nerve impulses. This produces reversible loss of sensation in the area of application.

Yes, Hexylcaine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1197. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 10770. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Aviso Médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.